Table 2
Non-ocular adverse events*
| Serious non-ocular adverse event | N (%) |
| All nervous system | 13 (2.3) |
| Cerebrovascular accident | 3 (0.5) |
| Cerebral infarction | 1 (0.2) |
| All cardiac | 30 (5.3) |
| Myocardial infarction | 4 (0.7) |
| Acute coronary syndrome | 1 (0.2) |
| Coronary artery occlusion | 1 (0.2) |
| Myocardial ischaemia | 1 (0.2) |
| All non-ocular haemorrhagic | 2 (0.4) |
| Haematuria | 1 (0.2) |
| Other non-ocular adverse events reported in over 2% of subjects | |
| Hypertension | 43 (7.6) |
| Urinary tract infection | 26 (4.6) |
| Sinusitis | 25 (4.4) |
| Gastro-oesophageal reflux | 21 (3.7) |
| Pneumonia | 20 (3.5) |
| Benign prostatic hyperplasia | 10 (4.3)† |
| Cardiac failure, congestive | 18 (3.2) |
| Bronchitis | 19 (3.3) |
| Nasopharyngitis | 16 (2.8) |
| Headache | 16 (2.8) |
| Nausea | 15 (2.6) |
